The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Prof. Stefano Luminari | ASH 2017 | IELSG-38: rituximab with chlorambucil for MALT lymphoma

Dec 10, 2017

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA
Professor Stefano Luminari

Rituximab with chlorambucil therapy followed by 2-year subcutaneous rituximab as new standard therapy

IELSG-38: rituximab with chlorambucil for MALT lymphoma